My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Telaprevir ( LY-570310; VX950; MP-424)
    Telaprevir ( LY-570310; VX950; MP-424)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0725
    CAS #: 402957-28-2Purity ≥98%

    Description: Telaprevir (also known as LY570310; VX-950; MP424; trade names: Incivek; Incivo), a marketed medication for HCV treatment, is a selective, and reversible peptidomimetic inhibitor of HCV NS3-4A serine protease with an IC50 of 0.35 μM. It belongs to the protease inhibitors class of antiviral drugs.  

    References: Antimicrob Agents Chemother. 2006 May;50(5):1813-22; Antimicrob Agents Chemother. 2006 Mar;50(3):899-909; J Hepatol. 2011 May;54(5):872-8.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)679.85
    FormulaC36H53N7O6
    CAS No.402957-28-2
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 136 mg/mL (200.0 mM)
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    Solubility (In vivo)30% PEG400+0.5% Tween80+5% propylene glycol: 30 mg/mL
    SynonymsVX-950, LY-570310, MP-424; VX950, LY570310, MP424; VX 950, LY 570310, MP 424; trade names: Incivek; Incivo 

    Chemical Name: (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide

    InChi Key: BBAWEDCPNXPBQM-GDEBMMAJSA-N

    InChi Code: InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1

    SMILES Code: O=C([[email protected]@H]1[[email protected]](CCC2)([H])[[email protected]]2([H])CN1C([[email protected]@H](NC([[email protected]](C3CCCCC3)NC(C4=NC=CN=C4)=O)=O)C(C)(C)C)=O)N[[email protected]@H](CCC)C(C(NC5CC5)=O)=O


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Telaprevir inhibits the hepatitis C virus NS3-4A serine protease, leading to the block of viral polyprotein processing and subsequently decrease of viral RNA replication, total HCV RNA levels and protein levels in the Con1 (genotype 1b) subgenomic HCV replicon cells in a time- and dose-dependent manner. Telaprevir displays a significant time-dependent increase in inhibitory effect on the replication of HCV RNA with IC50 values of 0.574 μM, 0.488 μM, 0.210 μM and 0.139 μM for 24, 48, 72 and 120 hours incubation, respectively. Telaprevir displays an average IC50 of 0.354 μM and an average IC90 of 0.830 μM, respectively, from three independent experiments using the 48 hours incubation. Telaprevir has no significant cytotoxicity to HCV replicon cells, parental Huh-7 and HepG2 cells after 48 hours incubation. Telaprevir (17.5 μM) completely eradicates HCV RNA from replicon cells after 13 days incubation without rebound after Telaprevir is withdrawn. Telaprevir displays an additive to moderate synergistic effect on reduction of HCV RNA replication and suppression of resistance mutations without significant increase in cytotoxicity when in combination with IFN-α, compared to treatment with each agent alone.


    Kinase Assay: Stable Huh-7 cells containing the self-replicating, subgenomic HCV replicon, which is identical in sequence to the I377neo/NS3-3'/wt replicon are used for anti-HCV assays. Replicon cells are incubated at 37 °C for the indicated period of time with Telaprevir serially diluted in DMEM plus 2% FBS and 0.5% dimethyl sulfoxide (DMSO). Total cellular RNA is extracted using an RNeasy-96 kit, and the copy number of HCV RNA is determined using a quantitative RTPCR (QRT-PCR) assay for the assessment of 50% inhibitory concentration (IC50).


    Cell Assay: Cells (Huh-7, HepG2, and peripheral blood mononuclear cells (PBMC)) are incubated with various concentrations of Telaprevir for 48 hours. Cell viability is determined by using a tetrazolium (MTS)-based cell viability assay.

    In VivoOral administration of Telaprevir reduces HCV protease-dependent cleavage and subsequent secretion of SEAP from the liver into the blood in the mice model to 18.7% and 18.4% at dosage of 10 and 25 mg/kg, respectively. Administration of Telaprevir at 200 mg/kg for 1 week results in a 1.9 log reduction of HCV RNA in genotype 1b HCV-infected human hepatocyte chimeric mice, and when treatment in combination with MK-0608 (50 mg/kg) for 4 weeks, viruses are eliminated from mice.
    Animal modelSCID mice injected with recombinant adenovirus (Ad-WT-HCVpro-SEAP or Ad-MT-HCVpro-SEAP) 
    Formulation & DosageFormulated in polyvinylpyrrolidone (PVP) K-30 plus 2% sodium lauryl sulfate; 300 mg/kg; P.O. 
    References

    Antimicrob Agents Chemother. 2006 May;50(5):1813-22; Antimicrob Agents Chemother. 2006 Mar;50(3):899-909; J Hepatol. 2011 May;54(5):872-8.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Telaprevir (VX-950)

    Reduction of HCV proteins in the replicon cells by VX-950. Antimicrob Agents Chemother. 2006 May;50(5):1813-22.

    Telaprevir (VX-950)

    Nine-day HCV replicon clearance assay. HCV replicon cells were incubated with various concentrations of VX-950 (A) or BILN 2061 (B) for 3, 6, or 9 days. Antimicrob Agents Chemother. 2006 May;50(5):1813-22.
     

    Telaprevir (VX-950)

    Time- and dose-dependent reduction of HCV RNA in the replicon cells by VX-950. Antimicrob Agents Chemother. 2006 May;50(5):1813-22.

    Telaprevir (VX-950)

    VX-950 prevents rebound of HCV replicon upon withdrawal of inhibitor. Antimicrob Agents Chemother. 2006 May;50(5):1813-22.

    Telaprevir (VX-950)

    Combination of VX-950 with IFN-α in the 48-h HCV replicon cell assay. Antimicrob Agents Chemother. 2006 May;50(5):1813-22.

    Telaprevir (VX-950)

    Combination of VX-950 and IFN-α in the 9-day HCV replicon clearance assay. Antimicrob Agents Chemother. 2006 May;50(5):1813-22.



    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?